Biopharmaceutical company Genfit, which specializes in the treatment of rare liver diseases, reports sales for fiscal 2023 of 28.6 million euros, compared with 20.2 million for the previous year.

It points out that 13.3 million in revenues are attributable to a milestone payment invoiced to Ipsen in December 2023, following acceptance of the NDA filing with the FDA and the filing of the MA application with the EMA for accelerated approval of elafibranor.

At December 31, 2023, Genfit's cash and cash equivalents amounted to 77.8 million euros (versus 140.2 million a year earlier), an amount not including the milestone payment from Ipsen, received in February 2024.

Copyright (c) 2024 CercleFinance.com. All rights reserved.